Melanoma Research

Article	Citations
Impact of COVID-19 on melanoma diagnosis	18
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)	17
The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials	17
C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting	16
Ultraviolet A radiation exposure and melanoma: a review	16
Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases	15
Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma	12
Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors	11
Hemophagocytic lymphohistiocytosis of a melanoma patient under BRAF/MEK-inhibitor therapy following anti-PD1 inhibitor treatment: a case report and review to the literature	11
Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study	10
The role of osteopontin in the development and metastasis of melanoma	10
Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma	10
Impact of the development of immune related adverse events in metastatic melanoma treated with PD -1 inhibitors	10
Ultra-high-frequency ultrasound monitoring of melanomas arising in congenital melanocytic nevi: a case series	10
Regression of nevi, vitiligo-like depigmentation and halo phenomenon may indicate response to immunotherapy and targeted therapy in melanoma	10
Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target	10
Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis	10
Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma	10
Efficacy of radiotherapy combined with immune checkpoint inhibitors in patients with melanoma: a systemic review and meta-analysis	10
A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors	9
Regular use of vitamin D supplement is associated with fewer melanoma cases compared to non-use: a cross-sectional study in 498 adult subjects at risk of skin cancers	9
Impact of staging on survival outcomes: a nationwide real-world cohort study of metastatic uveal melanoma	9
Aseptic cystitis induced by nivolumab and ipilimumab combination for metastatic melanoma	8
Vitamin D deficiency in melanoma patients is associated with worse overall survival: a retrospective cohort study	8
Diagnostic and prognostic value of heat shock protein 90α in malignant melanoma	8

Influence of IL1B (rs16944) and IL1R2 (rs4141134) polymorphisms on aggressiveness and prognosis of cutaneous melanoma	7
Statin use is associated with improved overall survival in patients with melanoma	7
Vitamin D insufficiency and serum levels related to the incidence and stage of cutaneous melanoma: a systematic review and meta-analysis	7
Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce anti-PD1	7
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activ	7
Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases	7
Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodies	7
ETS1 promoted cell growth, metastasis and epithelial–mesenchymal transition process in melanoma by regulating miR-16-mediated SOX4 expression	7
Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases	7
Combination of radiotherapy and targeted therapy for melanoma brain metastases: a systematic review	7
Clinical features, molecular characteristics and surgical management of primary penile mucosal melanoma based on the European Association of Urology Penile Cancer Guidelines	7
A novel prognostic biomarker for cutaneous malignant melanoma: red cell distribution width (RDW) to lymphocyte ratio	6
Risk factors in pediatric melanoma: a retrospective study of 39 cases	6
GLI-1 polymorphisms of Hedgehog pathway as novel risk and prognostic biomarkers in melanoma patients	6
Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy	6
Seborrheic keratosis-like melanoma: a diagnostic challenge	6
Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma	6
Antibody-drug conjugates: an evolving approach for melanoma treatment	6
A novel C-terminal Hsp90 inhibitor KU758 synergizes efficacy in combination with BRAF or MEK inhibitors and targets drug-resistant pathways in BRAF-mutant melanomas	6
Melanotransferrin is efficiently sorted on the surface of exosomes secreted by melanoma cells	6
The potential of using artificial intelligence to improve skin cancer diagnoses in Hawai‘i’s multiethnic population	6
Recombinant human Hsp110-gp100 chaperone complex vaccine is nontoxic and induces response in advanced stage melanoma patients	6
Retrospective analysis of adjuvant therapy using dabrafenib plus trametinib in Japanese patients with advanced melanoma: analysis of 36 cases	6
Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma	6
COVID-19 vaccination mimicking lymph-node progression in a patient with melanoma: a case report	6
Expression of the cancer stem cell marker OCT4 is associated with worse prognosis and survival in cutaneous melanoma	5
The role of artificial intelligence and convolutional neural networks in the management of melanoma: a clinical, pathological, and radiological perspective	5
Efficacy of immune checkpoint inhibition in metastatic uveal melanoma: a systematic review and meta-analysis	5
Female melanoma and estrogen receptors expression: an immunohistochemical pilot study	5
The human and animals’ malignant melanoma: comparative tumor models and the role of microbiome in dogs and humans	5
PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma	5
Proteomic profiles of melanoma cell-derived exosomes in plasma: discovery of potential biomarkers of melanoma progression	5
Immune-related Bell’s palsy in melanoma patients treated with immune checkpoint inhibitors	5
LINC01063 functions as an oncogene in melanoma through regulation of miR-5194-mediated SOX12 expression	5
Clinical performance indicators for monitoring the management of cutaneous melanoma: a population-based perspective	5
Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study	5
Tumor mutational burden and somatic mutation status to predict disease recurrence in advanced melanoma	5
BAP1 deletion abrogates growth and metastasis of murine cutaneous melanoma	5
MicroRNAs expression associated with aggressive clinicopathological features and poor prognosis in primary cutaneous melanomas	5
Identification of heterogeneity and prognostic key genes associated with uveal melanoma using single-cell RNA-sequencing technology	5
Expression of cathepsins B and D by cancer stem cells in head and neck metastatic malignant melanoma	5
Treatment of in-transit melanoma metastases using intralesional PV-10	4
Targeting cyclin-dependent kinase 4/6 as a therapeutic approach for mucosal melanoma	4
Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients	4
Real-world data on melanoma brain metastases and survival outcome	4
Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors	4
Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma	4
Induction of T helper 17 cell response by interleukin-7 in patients with primary cutaneous melanoma	4
PET-CT for staging pT4b melanomas prior to sentinel lymph node biopsy: a 5-year review	4
Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma	4

BRAF inhibitor treatment is feasible in the oldest-old advanced melanoma patients	4
Uveal melanoma metastatic at initial diagnosis: a case series	4
Exceptional response to combination ipilimumab and nivolumab in metastatic uveal melanoma: Insights from genomic analysis	4
Auto-immune hemolytic anemia and hemophagocytic lymphohistiocytosis as immune-related adverse event in patients with metastatic melanoma and concurrent chronic lymphocytic leukemia: a case series and	4
Immunohistochemistry analysis reveals lysyl oxidase-like 3 as a novel prognostic marker for primary melanoma	4
Neem leaf glycoprotein salvages T cell functions from Myeloid-derived suppressor cells-suppression by altering IL-10/STAT3 axis in melanoma tumor microenvironment	4
Nivolumab exposure in a hemodialysis patient with metastatic melanoma	3
Diagnostic and prognostic value of Beclin 1 expression in melanoma: a meta-analysis	3
Molecular profiling of primary uveal melanoma: results of a Polish cohort	3
Melanoma risk prediction based on a polygenic risk score and clinical risk factors	3
Clinicopathological features and programmed death-ligand 1 immunohistochemical expression in a multicenter cohort of uterine and ovarian melanomas: a retrospective study in Japan (KCOG-G1701s)	3
Expression of angiogenic and lymphangiogenic genes in primary cutaneous melanoma: relationship with angiolymphatic invasion and disease-free survival	3
Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series	3
Pembrolizumab-induced hypothyroidism manifesting as myopathy and psychosis	3
Real-world frequency of BRAF testing and utilization of therapies in patients with advanced melanoma	3
Histone deacetylase inhibitor Vorinostat (SAHA) suppresses micropthalmia transcription factor expression and induces cell death in nevocytes from large/giant congenital melanocytic nevi	3
Prognostic significance of tumor budding in melanoma	3
Leptomeningeal dissemination as a first sign of progression in metastatic melanoma: a diagnostic lesson	3
Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice	3
Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment	3
Knockdown of enhancer of rudimentary homolog expression attenuates proliferation, cell cycle and apoptosis of melanoma cells	3
Uveitis associated with immune checkpoint inhibitors or BRAF/MEK inhibitors in patients with malignant melanoma	3
The role of regional chemotherapy for advanced limb melanoma in the era of potentially effective systemic therapies	3
Sequential immunotherapy in melanoma: is it a realistic alternative to dual immunotherapy?	3
Robotic CyberKnife radiosurgery for small choroidal melanomas	3
Unexpected pure red series aplastic anemia secondary to pembrolizumab treatment: a case report and literature review	3
Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma	3
Talimogene laherparepvec monotherapy for head and neck melanoma patients	3
Metabolomic characterisation of progression and spontaneous regression of melanoma in the melanoma-bearing Libechov minipig model	3
Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene	3
Novel response to neoadjuvant anti-PD1 therapy for a patient with retrocaval melanotic schwannoma	3
Life-threatening polymyositis with spontaneous hematoma induced by nivolumab in a patient with previously resected melanoma	3
Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure	3
Cardiovascular disease and malignant melanoma	3
Patients with a history of atopy have fewer cutaneous melanomas than those without atopy: a cross-sectional study in 496 patients at risk of skin cancers	3
Uncomplicated pregnancy and delivery under ongoing nivolumab therapy for metastatic melanoma	3
Clinical characteristics and treatment outcomes of non-V600 E/K BRAF mutant melanoma patients: a single-institution experience	3
Melanoma-specific expression of the tumor suppressor proteins p16 and PTEN is a favorable prognostic factor in established melanoma brain metastases	3
B7H6 silencing increases chemosensitivity to dacarbazine and suppresses cell survival and migration in cutaneous melanoma	2
Updates on the diagnosis, current and future therapeutic options in Merkel-cell carcinoma	2
Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL)	2
The influence of metastatic patterns and tumor load on therapeutic efficacy of immunotherapy in patients with metastatic melanoma as determined by quantitative PET-parameters using [18F]-fluorodeoxygl	2
Infusion reaction to nivolumab in a metastatic melanoma patient. Safe switch to another anti-programmed death-1: a case report	2
Clostridium difficile infection and immune checkpoint inhibitor–induced colitis in melanoma: 18 cases and a review of the literature	2
Choroidal melanoma treatment in times of coronavirus disease 2019	2
Fertility preservation for patients with melanoma	2
A case of sudden brain metastases progression after temporary targeted therapy discontinuation: when to regret a drug holiday	2
Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands	2
A case of hyperprolactinaemia in a patient with metastatic melanoma	2
Electrical impedance spectroscopy significantly enhances correct biopsy choice for pigmented skin lesions beyond clinical evaluation and dermoscopy	2
Melanomas and mast cells: an ambiguous relationship	2
Melanoma risk during immunomodulating treatment	2
Exploring the role of epigenetic alterations and non-coding RNAs in melanoma pathogenesis and therapeutic strategies	2
Complete response of brainstem metastasis in BRAF-mutated melanoma without stereotactic radiosurgery after initiation of encorafenib and binimetinib	2
CD103 and periplakin are potential biomarkers for response of metastatic melanoma to pembrolizumab	2
Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients	2
Surgery of small bowel melanoma metastases in the era of efficient medical therapies: a retrospective cohort study	2
Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report	2
Sarcoid-like reaction in a BRAF V600E-mutated metastatic melanoma patient during treatment with BRAF/MEK-targeted therapy	2
Survival in adult patients with BRAFV600 mutation-positive advanced melanoma: a noninterventional ambispective study of patients with cobimetinib combined with vemurafenib during the French early acce	2
Use of laboratory hematology data in melanoma research: comments on “A novel prognostic biomarker for cutaneous malignant melanoma: red cell distribution width (RDW) to lymphocyte ratio” Melanoma Res	2
Successful use of rituximab for refractory hemophagocytic lymphohistiocytosis in a melanoma patient treated with targeted therapy	2
Novel strategy for applying hierarchical density-based spatial clustering of applications with noise towards spectroscopic analysis and detection of melanocytic lesions	2
Response to immune checkpoint inhibitor rechallenge after high-grade immune related adverse events in patients with advanced melanoma	2
DNA methylation of GITR, OX40, 4-1BB, CD27, and CD40 correlates with BAP1 aberrancy and prognosis in uveal melanoma	2
Noncontrast-enhanced 3-Tesla MRI using surface coil as a complementary test for assessment of distribution and depth of locoregional cutaneous metastases of malignant melanoma	2
Macrophage inhibitory cytokine-1 produced by melanoma cells contributes to melanoma tumor growth and metastasis in vivo by enhancing tumor vascularization	2
Melanoma-specific survival in worse in the elderly: a multicentric cohort study	2
Safety of immune checkpoint inhibitors after proton beam therapy in head and neck mucosal melanoma: a case series	2
Polymorphisms in toll-like receptor 3 and 4 genes as prognostic and outcome biomarkers in melanoma patients	2
Efficacy and safety of angiogenesis inhibitors in melanoma: a meta-analysis of seven randomized controlled trials	2
Long-term control of melanoma adrenal metastasis treated with radiotherapy	2
Orthotopic murine xenograft model of uveal melanoma with spontaneous liver metastasis	2
Extreme elevation of acute phase reactants and shock secondary to dabrafenib–trametinib	2
Isolated limb perfusion with melphalan as treatment for regionally advanced melanoma of the limbs: results of 60 patients treated in Finland during 2007–2018	2
Paradox in melanoma	2
Liver resection for metastatic uveal melanoma: experience from a supra-regional centre and review of literature	2
Impact of anesthesia choice in cutaneous melanoma surgery	2
MeVa2.1.dOVA and MeVa2.2.dOVA: two novel BRAFV600E-driven mouse melanoma cell lines to study tumor immune resistance	2
Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients	1

Connective tissue panniculitis and vitiligo in a patient with stage IV melanoma achieving complete response to dabrafenib and trametinib combination therapy	1
Severe treatment-induced inflammatory polyarthritis in advanced melanoma patients: 2 case reports	1
Tetrasomy of chromosomes 3 and 8 in a young male with choroidal melanoma	1
LS-007 inhibits melanoma growth via inducing apoptosis and cell cycle arrest and regulating macrophage polarization	1
Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma	1
Response of metastatic melanoma with a rare BRAF V600K mutation to dabrafenib and trametinib	1
Vitiligo-like hypopigmentation induced by dabrafenib-trametinib: a potential marker for clinical response	1
Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma	1
Clinicopathological demographics of malignant melanomas of the vulva and vagina in Japan	1
The immunologic balance: three cases of rituximab-associated melanoma	1
Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors	1
Global trends in cutaneous malignant melanoma incidence and mortality	1
Lenalidomide arrests cell cycle and modulates PD1-dependent downstream mTOR intracellular signals in melanoma cells	1
Treatment reality of patients with BRAF-mutant advanced/metastatic melanoma in Switzerland in the era of choice	1
Development and validation of a nomogram for elderly patients with ulcerative melanoma	1
Melanocytic neoplasms in neurofibromatosis type 1: a systematic review	1
Prognosis of CDKN2A germline mutation in patients with familial melanoma: a systematic review and meta-analysis	1
Efficacy of local ablative therapies in patients with solid tumors treated with immune checkpoint inhibitors and oligoprogression: a single-center analysis	1
Ponatinib-induced eruptive nevi and melanocytic proliferation	1
Prognosis of polypoid melanoma: a comparative study with non-polypoid melanomas	1
Brain metabolic changes in patients with disseminated malignant melanoma under immunotherapy	1
Mapping sentinel lymph nodes in cutaneous melanoma: a vast array of perioperative imaging modalities	1
The BRAF and NRAS status among distinct metastases of malignant melanoma differ significantly independent of tissue origin and temporal occurrence. Possible effect on clinical relevance?	1
Immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies, in a patient with melanoma treated with BRAF/MEK inhibitors	1
Morphea following treatment with pembrolizumab for melanoma with metastatic lymph nodes: case report and review of literature	1
The combination of PAC-1 and entrectinib for the treatment of metastatic uveal melanoma	1
Melanoma cell plasticity poses diagnostic challenges: a case series	1
Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma	1
Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis	1
Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients	1
Cost-effectiveness analysis of an orphan drug-tebentafusp in patients with metastatic uveal melanoma and a call for value-based pricing	1
Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel	1
Clinical and genetic determinants of vitamin D receptor expression in cutaneous melanoma patients	1
Clinical and dermoscopical presentation of nivolumab-induced pemphigoid in a metastatic melanoma patient	1
Eruptive melanocytic nevi in a patient with amelanotic melanoma: a paraneoplastic phenomenon?	1
Chemical features of melanoma tumor resident TRG CDR3s associated with better survival probabilities	1
Nodular type predominance of head and neck cutaneous malignant melanoma in Asian populations leads to poor outcome and low survival	1
Targeting beta-adrenergic receptor pathways in melanoma: how stress modulates oncogenic immunity	1
Prospective study of clinical characteristics of melanoma patients with retinopathy caused by a high-dose interferon α-2b	1
Mucosal melanoma: from molecular landscape to current treatment strategies	1
High expression of GRB2 associated binding protein 3 mRNA predicts positive prognosis in melanoma	1
Clinical significance of CCNE1 copy number gain in acral melanoma patients	1
Management of heterogeneous tumor response patterns to immunotherapy in patients with metastatic melanoma	1
Study of clinical characteristics and risk factors for amelanotic/hypomelanotic melanoma in an Australian cohort	1
Correlation of MRI signal characteristics of intracranial melanoma metastases with BRAF mutation status	1
The effect of COVID-19 on early melanoma detection	1
Pregnancy-associated melanoma: characteristics and outcomes from 2002 to 2020	1
Sentinel node biopsy in cutaneous melanoma patients with germline CDKN2A mutations	1
Immunotherapy-induced granulomatous reaction in patients with melanoma	1
Dacarbazine in the management of metastatic melanoma in the era of immune checkpoint therapy: a valid option or obsolete?	1
Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in skin cutaneous melanoma	1
Histopathological and immunological spectrum in response evaluation of talimogene laherparepvec treatment and correlation with durable response in patients with cutaneous melanoma	1
Preoperative assessment of cutaneous melanoma thickness by multispectral dermoscopy	1
Comprehensive clinical imaging, histopathological analysis and liquid biopsy-based surveillance of human uveal melanoma in a prolonged rabbit xenograft model	1
Management of metastatic bone disease of melanoma	1
Quality of life after melphalan percutaneous hepatic perfusion for patients with metastatic uveal melanoma	1
BRCA1-associated protein 1 c.368delG mutation leads to the development of multiple BAPomas and cutaneous melanomas: a novel pathogenic variant in BRCA1-associated protein tumor predisposition syndrome	1
Telomere length is associated with increased risk of cutaneous melanoma: a Mendelian randomization study	1
Underreporting of acral lentiginous melanoma in studies informing American Joint Committee on Cancer Staging System Guidelines: a review of 150 cited studies	1